Answers are grounded in this paper and cite their sources.
Background Cell-bound complement activation products (CB-CAPs) are potential diagnostic markers for systemic lupus erythematosus (SLE). Existing studies adopted inconsistent cell types, cutoffs, algorithms, and control groups. This review analyzed distinct CB-CAP markers separately without uniform treatment of different CB-CAP tests. Methods Embase and Web of Science were searched from inception to August 18, 2026, and PubMed/MEDLINE was searched from inception to September 27, 2026. Eligible studies evaluated a blood-cell-bound complement marker or CB-CAP-based algorithm in SLE and non-SLE controls and provided threshold-specific sensitivity and specificity or reconstructable 2 × 2 data. Two reviewers independently screened records, extracted data, and performed QUADAS-2 assessment, with disagreements adjudicated by a third reviewer. The primary analysis comprised adult B-cell-bound C4d (BC4d) versus clinical disease controls with one record per independent cohort. A Reitsma-type bivariate random-effects model jointly synthesized logit sensitivity and specificity; post hoc separate univariate random-effects and leave-one-out analyses examined the robustness of the findings to the small number of studies. Results A total of 10 eligible reports were retained: nine primary diagnostic studies and one 2026 multicohort aggregate report that re-used participants enrolled during 2011–2025 and was therefore not treated as an independent observation. Four adult BC4d studies contributed 611 SLE cases and 602 clinical controls to the primary model. Summary sensitivity was 47.7% (95% confidence interval [CI], 32.7%–63.1%), and specificity was 91.3% (95% CI, 82.6%–95.9%). The approximate positive and negative likelihood ratios were 5.50 and 0.57, respectively. Prediction intervals were wide (sensitivity, 19.0%–78.0%; specificity, 68.7%–98.1%). Separate univariate random-effects estimates were similar (sensitivity, 47.9%; specificity, 91.6%), while leave-one-out estimates ranged from 41.7% to 53.6% for sensitivity and from 85.1% to 94.5% for specificity. All 10 reports had high risk of bias in patient selection; seven had high risk and one had unclear risk in the index-test domain. Conclusions BC4d exhibits higher specificity than sensitivity for SLE diagnosis. A positive BC4d result raises SLE probability but requires combined assessment of pretest probability and clinical evidence and cannot independently confirm or exclude uncertain SLE cases. Evidence for other CB-CAP markers and combined tests remains limited, requiring further external validation in consecutive patient cohorts.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: